ERBB2 and ductal breast carcinoma in situ: Some multiple epitope vaccines showed in vivo efficacy with promising protective immunity [45,46,48,103], while some have entered into phase-I clinical trials, including H2NVAC in patients with HER2-expressing ductal carcinoma in situ (DCIS) (NCT03793829), E1602 for patients with metastatic melanoma [111], EMD640744 in patients with advanced solid tumors [104], and TAB9 in non-HIV-1 infected human volunteers [112].